Eton Pharmaceuticals Inc. (ETON) Misses Q2 EPS by 5c

Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q2 EPS of ($0.12), $0.05 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $9.07 million versus the consensus estimate of $8.8 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.

You May Also Be Interested In

• Abu Dhabi's G42 Weighs US Ownership To Safeguard AI Chip Access - Bloomberg
• US 2-year Yield Rises To 4.416%, Highest Since January 2025
• Concrete Pumping Holdings (BBCP) Tops Q3 EPS by 1c